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MaBACKGROUND Increases in serum creatinine (DSCr) from baseline signify acute kidney injury (AKI) but offer little
granular information regarding its characteristics. The 10th Consensus Conference of the Acute Dialysis Quality Initiative
(ADQI) suggested that combining AKI biomarkers would provide better precision for AKI course prognostication.
OBJECTIVES This study investigated the value of combining a functional damage biomarker (plasma cystatin C [pCysC])
with a tubular damage biomarker (urine neutrophil gelatinase-associated lipocalin [uNGAL]), forming a composite
biomarker for prediction of discrete characteristics of AKI.
METHODS Data from 345 children after cardiopulmonary bypass (CPB) were analyzed. Severe AKI was deﬁned as Kidney
Disease Global Outcomes Initiative stages 2 to 3 ($100% DSCr) within 7 days of CPB. Persistent AKI lasted>2 days. SCr in
reversible AKI returned to baseline #48 h after CPB. The composite of uNGAL (>200 ng/mg urine Cr ¼ positive [þ]) and
pCysC (>0.8 mg/l ¼ positive [þ]), uNGALþ/pCysCþ, measured 2 h after CPB initiation, was compared to DSCr increases
of $50% for correlation with AKI characteristics by using predictive probabilities, likelihood ratios (LR), and area under
the curve receiver operating curve (AUC-ROC) values.
RESULTS Severe AKI occurred in 18% of patients. The composite uNGALþ/pCysCþ demonstrated a greater likelihood
than DSCr for severe AKI (þLR: 34.2 [13.0:94.0] vs. 3.8 [1.9:7.2]) and persistent AKI (þLR: 15.6 [8.8:27.5] versus 4.5
[2.3:8.8]). In AKI patients, the uNGAL/pCysCþ composite was superior to DSCr for prediction of transient AKI.
Biomarker composites carried greater probability for speciﬁc outcomes than DSCr strata.
CONCLUSIONS Composites of functional and tubular damage biomarkers are superior to DSCr for predicting discrete
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ABBR EV I A T I ON S
AND ACRONYMS
AKI = acute kidney injury
AUC = area under the curve
CART = classiﬁcation and
regression tree analysis
CPB = cardiopulmonary bypass
LR = likelihood ratio
pCysC = plasma cystatin C
uNGAL = urinary neutrophil
gelatinase-associated lipocalin
uNGALþ/pCysCþ =
biomarker composite
designating both >200 ng/mg
uNGAL and >0.8 mg/l pCysC
DSCr = change in serum
creatinine from baseline
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2754strategy can be variable, and best practice
guidelines have not yet been widely dissem-
inated (5).
Imprecise diagnoses may lead to imprecise
therapy. AKI is a syndrome caused by a wide
variety of pathophysiologic processes (e.g.,
sepsis and post-cardiopulmonary bypass
[CPB]) and does not manifest equally in all
patients. Unfortunately, whereas AKI occurs
along a spectrum and is heterogeneous from
patient to patient, identiﬁcation of AKI by
serum creatinine (SCr) is binary (AKI or no
AKI) and offers no ability to predict the
outcome or otherwise deﬁne more speciﬁc
characteristics of the injury. Additionally, the
current nomenclature for AKI diagnosis is
problematic. Terms such as “pre-renal” and“intrinsic renal” are simplistic and may erroneously
imply speciﬁc pathophysiology, location of injury,
and severity of damage, potentially leading to thera-
peutic imprecision. For example, ﬂuid resuscitation,
often the ﬁrst course of action in a patient with severe
dehydration, can be quite deleterious in a patient
with congestive heart failure, even though both have
the same AKI classiﬁcation of “pre-renal” AKI (6). Pre-
renal AKI is also often equated with a pathophysio-
logic description of reversibility or transient AKI,
potentially rendering the erroneous conclusion that
this type of AKI reﬂects less damage to the kidney.
Intrinsic renal AKI is often considered severe and
interchangeable with “acute tubular necrosis,” which
may be pathologically inaccurate; available histologic
evidence does not consistently match the necrotic
shape of renal tubules to a level of renal dysfunction
(7). Thus, an approach to AKI using objective, repro-
ducible metrics may be advantageous (8,9).SEE PAGE 2763Use of novel biomarkers indicative of different AKI
pathophysiological conditions and carrying different
temporal proﬁles in relation to injury may enhance
diagnostic precision (10,11). The 10th Consensus Con-
ference of the Acute Dialysis Quality Initiative (ADQI)
recommended testing the efﬁcacy of novel AKI bio-
markers in combination with functional biomarkers
to more precisely delineate and deﬁne AKI charac-
teristics (12). Identiﬁcation of AKI phenotypes using
these biomarkers may be a way to disentangle the
AKI syndrome (13,14).
In this study, we tested the performance of dif-
ferent combinations of 2 novel biomarkers, a func-
tional injury marker and a tubular damage marker, to
reﬁne the granularity of AKI diagnosis. We compared
the abilities of these biomarker combinations topredict creatinine-based discrete AKI outcomes (us-
ing Kidney Disease Global Outcomes Initiative
[KDIGO] AKI stages 2 to 3) with that of SCr itself to
predict outcomes for AKI. Our ﬁndings demonstrated
that combining biomarkers allows for prediction of
temporal and pathophysiologic characteristics of
injury, increasing the precision of AKI diagnosis in
ways not possible with SCr alone.
METHODS
The Institutional Review Board of Cincinnati Chil-
dren’s Hospital Medical Center approved this study.
The study is a retrospective review of children <18
years of age undergoing CPB, enrolled from January
2004 to May 2007 at our institution, initially in
a study examining biomarkers and AKI after CPB.
Before enrollment, written informed consent was
obtained from the legal guardians of all patients, with
assent from the patients, when appropriate (15). Pa-
tients with pre-existing kidney function insufﬁciency
(deﬁned as a baseline SCr concentration >2 the age-
adjusted reference range) were excluded. All patients
were admitted to the cardiac intensive care unit
(CICU) following surgery.
Patient data were collected from the pre-operative
period to CICU post-operative day 7 (POD7). Demo-
graphic data included hospital admission date, CICU
admission date, CICU discharge date, hospital dis-
charge date, prematurity; and sex, race, age, height,
and weight. Procedural cardiac data collected in-
cluded CPB history and CPB time; surgical complexity
score using Risk Adjustment Congenital Heart Sur-
gery Score 1 (RACHS-1) (16); and surgical procedure
type. Post-operative CICU outcome data included
length of stay, death, and provision of renal replace-
ment therapy. Indices speciﬁc for kidney function
included baseline SCr, ﬁrst post-operative SCr, and
SCr from POD1 and 2. The ﬁrst post-operative SCr level
was measured on arrival at the CICU, after surgery.
Data for this study included serum and urine sam-
ples. Samples were stored in aliquots at 80C until
measurement (17). Urinary biomarkers used in this
study were measured 2 h after initiation of CPB, and
included urinary creatinine and neutrophil gelatinase-
associated lipocalin (uNGAL), measured by an
enzyme-linked immunoassay kit (product no. 036,
AntibodyShop, Grusbakken, Denmark) that speciﬁcally
detects human NGAL (15). The concentration of serum
cystatin C, also measured 2 h after initiation of CPB,
was quantiﬁed by nephelometry using a standardized
clinical laboratory platform (BN ProSpec, Dade-Behring,
Newark, Delaware), according to the manufacturer’s
recommendations (18). For the original study,
FIGURE 1 Side-by-Side 2  2 Tables Show 4 Different AKI Phenotypes Based
on Pathophysiology of Injury Versus Translation When Using Combinations of
Biomarkers to Detect the Corresponding Injuries
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Transient AKI, formerly known as “pre-renal” AKI, falls into the category of loss of function
without damage (bottom left of each table). Damage with loss of function is a combination
of functional and tubular injury. Adapted with permission from Endre et al. (6). AKI ¼
acute kidney injury.
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2755biomarkers were collected at 2, 6, 12, 24, and 48 h after
initiation of CPB. Measurement of SCr during CPB is
not standard of care and was not routinely performed.
The primary outcome variable was development of
severe AKI, deﬁned as KDIGO stage 2 or 3 on any POD,
using creatinine-based KDIGO stage deﬁnitions,
where stage 1 ¼ 1.5 to 1.99 baseline SCr; stage 2 ¼ 2
to 2.99 baseline SCr; and stage 3 ¼ $3 baseline SCr
(5). Duration of severe AKI was classiﬁed into 1 to
2 days or >2 days (indicating persistent AKI). Among
patients who developed severe AKI, the return of
SCr to baseline at <48 h was deﬁned as transient
(reversible) AKI. To derive decision trees, we used
classiﬁcation and regression tree (CART) analysis.
The CART algorithm can operate using supervised
decision rules (i.e., a priori deﬁned cutoff values) or
unsupervised decision rules, deriving decision nodes
that maximally discriminate between AKI and no
AKI (or other outcomes of interest) (19). The trees
were built using Salford Predictive Modeler version
6.6 software (Salford Systems, San Diego, California).
Performance of the tree was reported using diagnostic
test statistics with 95% conﬁdence intervals com-
puted using MedCalc for statistical computation (20).
Areas under the receiver operating characteristic
curve (AUC-ROC) were derived.
Biomarker composites were created for comparison
of changes in creatinine concentration for prediction
of outcomes. For this primary analysis, measurements
of biomarkers at 2 h into CPB procedure were used.
Using this time point for biomarker analysis theoreti-
cally offered the most meaningful yield for early pre-
diction of AKI versus changes in SCr (median time was
5 to 6 h after CPB initiation in our cohort). The com-
posites combined a functional injury marker, plasma
cystatin C (pCysC), with the tubular damage biomarker
(uNGAL). Four unique composites were created using
combinations denoting positivity or negativity of each
biomarker relative to reference cutoffs for injury
(Figure 1). Urinary NGAL was normalized to urinary
creatinine (uNGAL/uCr). A cutoff of 200 ng/mg was
used to denote uNGAL/uCr positivity (derived from
reference values of 100 ng/ml for uNGAL and 0.5 mg/
ml of uCr) and 0.8 mg/l for pCysC positivity (21–23).
The notation for a composite is “uNGAL/pCysC,” with
the inclusion of “þ” or “” sign for each biomarker,
depending on its value relative to cutoff values.
Biomarker composites were compared to changes in
SCr from baseline (pre-operative) to ﬁrst post-
operative check (DSCr). The primary cutoff value
used to denote a positive DSCr was $50%, equivalent
to 1.5 times baseline ($KDIGO stage 1).
STATISTICAL ANALYSIS. Data are described using
medians, interquartile ranges (IQR), frequencies, andpercents. Outcome comparisons used the Mann-
Whitney U test, chi-square test, or Fisher exact test,
as appropriate. Descriptive statistics and compari-
sons were analyzed using SigmaStat version 12.3
software (San Antonio, Texas). Likelihood ratios (LR)
were derived using standard calculation formats,
where þLR ¼ (sensitivity/[1  speciﬁcity]); LR ¼
([1  sensitivity]/speciﬁcity), by MedCalc. A signi-
ﬁcant elevation in LR was denoted by a 95% conﬁ-
dence interval (CI) that did not cross 1. Signiﬁcance
of the differences among LRs was determined by
lack of overlap between 95% CI. CART decision tree
derivation was performed both with and without
restrictions (i.e., supervised and unsupervised) for
DSCr cutoff values.
RESULTS
AKI HAS A HIGH PREVALENCE AND IS ASSOCIATED
WITH INCREASED MORBIDITY. Severe AKI occurred
in 18% (62 of 345) of patients. Only younger age was
associated with AKI; demographics of patients with
or without AKI were otherwise similar. Surgical
complexity scores did not differ between patients
with versus those without severe AKI. Patients with
severe AKI had higher mortality rates, longer CPB
times, and longer lengths of CICU stay (Table 1).
DOUBLE-POSITIVE BIOMARKER COMPOSITE (UNGALD/
PCYSCD) DEMONSTRATES SIGNIFICANTLY SUPERIOR
PREDICTIVE PERFORMANCE FOR SEVERE AKI. Dual
positivity in the biomarker composite (uNGAL >200
ng/mg and pCysC >0.8 mg/l) was more predictive of
severe AKI than positivity of DSCr (change $50%)
(Table 2). The uNGALþ/pCys composite biomarker
TABLE 1 Demographics
Total No AKI AKI
n (%) 345 283 (82) 62 (18)
Age, yrs 1.05 (0.43–4.44) 1.75 (0.46–5.1) 0.52 (0.32–0.85)*
Male 184 (53) 156 (55) 28 (45)
History of CPB 148 (43) 130 (46) 18 (29)
RACHS-1 class 2 (2–3)
6: 6
5: 5
4: 11
3: 127
2: 162
1: 34
2 (2–3)
6: 5 (1.7)
5: 3 (1.1)
4: 10 (3.5)
3: 106 (37.5)
2: 125 (44.2)
1: 34 (12.0)
2 (2–3)
6: 1 (1.6)
5: 2 (3.2)
4: 1 (1.6)
3: 21 (33.8)
2: 37 (59.7)
1: 0
CPB time, min 101 (74–145) 95 (71–134) 135 (89–192)*
ICU length of stay, days 5 (4–10) 5 (4–8) 11 (6–21)*
Mortality 6 (1.7) 4 (1.4) 2 (3.2)
Values are n, n (%), or median (IQR). Patients studied were separated by the development of
acute kidney injury (AKI) within the ﬁrst 7 days after cardiopulmonary bypass (CPB). *p < 0.001
for AKI versus no AKI.
ICU ¼ intensive care unit; IQR ¼ interquartile range; RACHS-1 ¼ Risk Adjustment for Congenital
Heart Surgery-1 score.
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than did DSCr.
DOUBLE-POSITIVE BIOMARKER COMPOSITE (UNGALD/
PCYSCD) DEMONSTRATES SUPERIOR PREDICTIVE PER-
FORMANCE FOR PERSISTENT AKI. The dual-positive
uNGALþ/pCysCþ composite was a better predictor
of persistent AKI than DSCr $50% (Table 3). The
uNGALþ/pCyspCys composite also trended toward
better prediction of persistent AKI than DSCr $50%.
IN PATIENTS WHO DEVELOPED AKI, A BIOMARKER
COMPOSITE OF FUNCTIONAL DAMAGE POSITIVITY
BUT TUBULAR DAMAGE NEGATIVITY (UNGALL/
PCYSD) IDENTIFIES TRANSIENT INJURY. In the 62
patients who developed AKI post-operatively, 29
experienced AKI at >2 days. The uNGAL/pCysþ
composite identiﬁed patients with transient AKI withTABLE 2 Prediction of Severe AKI by Biomarker Composites
Marker Sensitivity Speciﬁcity PPV
DSCrþ 22 (13–35) 94 (91–96) 45 (27–64)
uNGAL
pCysC
5 (1–14) 46 (41–52) 2 (0–6)
uNGAL
pCysCþ
23 (13–35) 57 (50–63) 10 (6–17)
uNGALþ
pCysC
24 (14–37) 98 (96–99) 75 (51–91)
uNGALþ
pCysCþ
48 (36–61) 99 (96–100) 88 (73–97)
Sensitivity, speciﬁcity, positive predictive value (PPV), and negative predictive value (NP
lipocalin (uNGAL) and plasma cystatin C (pCysC) in relation to their respective cutoff va
prediction of severe acute kidney injury (AKI) compared to the change in serum creatini
of $50% increase). uNGAL is normalized to urinary creatinine.
LR ¼ likelihood ratio.100% speciﬁcity and 100% positive predictive value
(PPV) (Table 4). Analysis of DSCr at multiple thresh-
olds did not demonstrate a statistically signiﬁcant
ability to distinguish patients with transient AKI
from patients who developed AKI. Additionally, the
uNGALþ/pCysCþ composite demonstrated a signiﬁ-
cantly negative LR for transient AKI. When the com-
posites were tested relative to the entire cohort of
345 patients, the þLR for uNGAL/pCysCþ to predict
transient AKI was 5.2 (1.8 to 15.5) versus 0.7 (0.4
to 14.4) and 0.3 (0.1 to 0.6) for DSCr of 25 to 49.9%
and $50%, respectively (Figure 2).
USE OF BIOMARKER COMPOSITES YIELDS A SIGNIFI-
CANTLY HIGHER PREDICTIVE DISCRIMINATION
BETWEEN SEVERITY AND PERSISTENCE OF AKI THAN
DSCR. Use of CART analysis demonstrated the superior
predictive precision of biomarker composites for AKI
severity (Figure 3) and AKI persistence (Figure 4)
compared to DSCr. The probabilities of severe AKI
and persistent AKI in the terminal nodes, using su-
pervised decision rules for pCysC (>0.8 mg/l) and
uNGAL (>200 ng/mg), are approximately twice the
probabilities in the terminal nodes, using the CART-
derived optimal unsupervised cutoff value for DSCr
(89% vs. 43% for AKI KDIGO stages 2 to 3 and 57% vs.
29% for persistent AKI, respectively). Additionally, the
AUC-ROC of each outcome was higher for the com-
posites than for even themost optimal DSCr derived by
CART (29.2% for AKI severity and 45% for AKI persis-
tence). CART identiﬁed optimal unsupervised cutoff
values for pCysC of 0.9 mg/l and 1.2 mg/l, leading to
AUC values of 0.63 and 0.59 for discrimination of se-
vere AKI and persistent AKI, respectively. Similarly,
optimal unsupervised cutoff values for uNGAL of 61
ng/ml and 130 ng/ml led to AUC values of 0.90 and 0.89
for severe AKI and persistent AKI, respectively.NPV þ LR LR
85 (80–89) 3.8 (1.9–7.2) 0.8 (0.7–0.9)
69 (62–76) 0.1 (0–0.3) 2.0 (1.8–2.3)
77 (71–82) 0.5 (0.3–0.8) 1.4 (1.2–1.6)
75 (51–91) 13.7 (5–36) 0.8 (0.7–0.9)
90 (86–93) 34.2 (13–94) 0.5 (0.4–0.7)
V) are % (95% CI). Biomarker composites of urinary neutrophil gelatinase-associated
lues for positivity (þ) >200 ng/mg and 0.8 mg/l demonstrate signiﬁcantly improved
ne (DSCr) from pre-operative to ﬁrst post-operative value (cutoff value for positivity
TABLE 3 Prediction of AKI >2 Days by Biomarker Composites
Marker Sensitivity Speciﬁcity PPV NPV þ LR LR
D SCr þ 31 (15–51) 93 (90–96) 29 (14–48) 93 (90–96) 4.5 (2.3–8.8) 0.7 (0.6–0.9)
uNGAL
pCysC
7 (1–23) 52 (46–58) 1.3 (0.2–4.6) 86 (80–90) 0.1 (0–0.6) 1.8 (1.5–2.0)
uNGAL
pCysCþ
0 (0–16) 57 (51–62) 0 (0–3) 89 (83–93) 0 (NC) 1.8 (1.6–1.9)
uNGALþ
pCysC
24 (10–44) 96 (93–98) 35 (15–59) 93 (90–96) 5.9 (2.5–13.5) 0.8 (0.6–1.0)
uNGALþ
pCysCþ
69 (49–85) 96 (93–98) 59 (41–75) 97 (95–99) 15.6 (8.8–27.5) 0.3 (0.2–0.6)
Sensitivity, speciﬁcity, PPV, and NPV are % (95% CI). Biomarker composites of uNGAL and pCysC in relation to their respective cutoff values for positivity (þ) >200 ng/mg and
0.8 mg/l demonstrate signiﬁcantly improved prediction of the duration of severe AKI compared to the DSCr from pre-operative to ﬁrst post-operative value (cutoff value for
positivity of $50% increase). uNGAL is normalized to urinary creatinine.
Abbreviations as in Table 2.
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In this study, we operationalized an objective of the
ADQI workshop, combining novel AKI biomarkers
representative of different types of renal injury to
improve the precision of AKI course prognostication
(6,9). We demonstrated that a composite of bio-
markers, including a marker indicative of functional
glomerular damage (cystatin C) and amarker of tubular
damage (NGAL), yields greater predictive precision
for discrete SCr-based AKI outcomes than DSCr anal-
ysis by itself. By combining novel biomarkers, both
temporal and pathophysiologic information about
AKI after CPB can be predicted (Central Illustration).
Prediction of AKI severity and duration is
more robust using biomarker composites than using
changes in creatinine concentration. Severe AKI pre-
valence in our cohort was 18% and was associated
with the well-established risk factors of younger age
and longer CPB times. In addition, severe AKI was
associated with longer ICU stay. Although DSCr pre-
dicted severe AKI with a reasonably high speciﬁcityTABLE 4 Prediction of Transient AKI by Biomarker Composites
Marker Sensitivity Speciﬁcity PP
DSCr 0%–24% 42 (25–61) 59 (39–77) 54 (33
DSCr 25%–49% 24 (11–42) 83 (64–94) 62 (32
DSCr $50% 15 (5–32) 69 (49–85) 36 (13
uNGAL
pCysC
3 (0–16) 93 (77–99) 33 (5–
uNGAL
pCysCþ
42 (25–61) 100 (88–100) 100 (77
uNGALþ
pCysC
24 (11–42) 76 (56–90) 53 (27
uNGALþ
pCysCþ
30 (16–49) 31 (15–51) 33 (17
Sensitivity, speciﬁcity, PPV, and NPV are % (95% CI). For patients who developed AKI (
cutoff values for positivity $200 ng/mg and 0.8 mg/l (þ) demonstrate the ability to us
superior to that afforded by any DSCr from pre-operative to ﬁrst post-operative value.
Abbreviations as in Table 2.and predictive value, the þLR of severe AKI, using
a composite of functional and tubular injury, was
w10 stronger (LR of 34.2 vs. 3.8, respectively).
Additionally, the PPV was 2 higher (88% vs. 45%,
respectively), and the negative predictive value
(NPV) was 90% for the double-positive composite.
Conversely, the LR of uNGAL/pCyspCys was
negative, indicating that kidney injury was unlikely.
Finally, the likelihood of severe AKI differed among
the 4 possible biomarker composites, suggesting
that pathophysiological differences in AKI exist.
The prediction of persistent AKI was similarly more
robust using the biomarker composites than the
DSCr. The population of patients with persistent AKI
(8.4% [29 of 345]) had an associated CPB time of 174
min (IQR: 125 to 224 min) and length of stay of 19
days (IQR: 11 to 28 days). Using the uNGALþ/pCysCþ
composite for prediction of persistent AKI, the þLR
wasw3.5 that using DSCr (15.6 vs. 4.5, respectively).
Once again, the PPV was nearly 2 higher (59% vs.
29%, respectively). The NPV for uNGALþ/pCysCþ
was 96%.V NPV þ LR LR
–74) 47 (30–65) 1.0 (0.6–1.9) 1.0 (0.6–1.5)
–86) 49 (34–64) 1.4 (0.5–3.8) 0.9 (0.7–1.2)
–65) 42 (28–57) 0.5 (0.2–1.3) 1.2 (0.9–1.6)
88) 46 (33–59) 0.4 (0–4.6) 1.0 (0.9–1.2)
–100) 60 (45–74) NC 0.6 (0.4–0.8)
–79) 47 (32–62) 1.0 (0.4–2.4) 1.0 (0.8–1.3)
–53) 28 (14–47) 0.4 (0.3–0.8) 2.3 (1.3–4.0)
62 of 345), biomarker composites of uNGAL and pCysC in relation to their respective
e composite biomarker panels to identify transient injury. Prediction was signiﬁcantly
uNGAL is normalized to urinary creatinine.
FIGURE 2 Transposition of Table of Likelihood Ratios Next to 2  2 Tables From Figure 1 Allows Visualization of the
Predictive Power of Composites of Biomarkers Representative of Pathophysiologic Types of Injury
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 loss of function
Damage
Present –
–
+
+
Urinary neutrophil gelatinase-associated lipocalin (uNGAL) was used as a tubular damage marker, and plasma cystatin C (pCysC) was used as a
functional damage marker. Prediction of transient acute kidney injury (denoted as a loss of function without damage) between the biomarker
composites (bottom left of the far right table) should be compared to the post-operative percent of creatinine changes (DSCr; bottom right
table). Data are for the entire cohort of 345 patients with 95% conﬁdence intervals listed for the positive (D) and negative (L) likelihood ratios.
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2758Biomarker measurements occurred notably before
the ﬁrst post-operative SCr measurement. In most
cases, biomarkers were measured 2 to 3 h after
CPB initiation, whereas the ﬁrst post-operative Cr
measurement was obtained 5 to 6 h after CPBFIGURE 3 Decision Trees Created by CART Analysis Demonstrate Di
and Composites of uNGAL and pCysC
uNGAL/pCys C
uNGAL > 200
uNGAL ≤ 200 uNGAL ≤ 200uNGAL ≥ 200
pCysC > 0.8
pCysC > 0.8pCysC < 0.8
n
All Patients 
Outcome #
# #
Rate
Rate
# Rate # Rate
Rate
No AKI
Severe AKI
Outcome 
No AKI
Severe AKI
Outcome 
No AKI
Severe AKI
Outcome 
No AKI
Severe AKI
# RateOutcome 
No AKI
Severe AKI
Outcome 
No AKI
Severe AKI
N=345 
N=169 
N=150 N=19 N=141
N=176
283 
152 
147 5
143
0.98 0.26 127
14
0.91
0.090.740.02
17 
0.90
0.10
0.74
0.2645 
131 
62 
0.82 
0.18
150
141
19
35
2
9
74
89
AKI %
– –
–
–
+
+
+ +
The terminal node of the supervised decision rules for uNGAL (ng/mg urin
versus 43% for the unsupervised rule for DSCr (>29.2%). CART analysis
the biomarker composite than the creatinine change. No AKI is deﬁned
7 days of surgery. AKI ¼ acute kidney injury; AUC-ROC ¼ areas under th
regression tree; KDIGO ¼ Kidney Disease Global Outcomes Initiative; otinitiation. Assessment of kidney health at 2 h into CPB
procedure carries an obvious beneﬁt for optimal post-
operative or intraoperative management. Even if
uNGAL is measured 6 h after CPB initiation (at around
the same time as most of the ﬁrst post-operative SCrfferences in Discrimination for Severe AKI by DSCr
Δ SCr
Δ SCr ≤ 29.2 N=273
Δ SCr > 29.2%
SCr > 29.2% n AKI %
–
+
273
72
11
43
uNGAL > 200
uNGAL ≥ 200
pCysC > 0.8# RateOutcome 
No AKI
Severe AKI
N=35
4
31
0.11
0.89
All Patients 
Marker Sensitivity Specificity AUC
Outcome 
Outcome 
# Rate
# Rate
No AKI
No AKI
Severe AKI
Severe AKI
Δ SCr ≤ 29.2 N=72
Outcome # Rate
No AKI
Severe AKI
N=345 
283 
242 41
31
0.57
0.43
0.89
50%
73% 97% 0.90
86% 0.68
0.1131
62 
0.82 
0.18
ary creatinine) and pCysC (mg/l) shows 89% probability of severe AKI
also demonstrated a higher sensitivity, speciﬁcity, and AUC-ROC for
as no injury or KDIGO stage 1; severe AKI is KDIGO stage 2 or within
e receiver operating characteristic curve; CART ¼ classiﬁcation and
her abbreviations as in Figure 2.
FIGURE 4 Decision Trees Created by CART Analysis Demonstrate Differences in Discrimination for Persistence of AKI
by DSCr and Composites of uNGAL and pCysC
uNGAL/pCys C
uNGAL > 200 pCysC > 0.8 n AKI %
150 1
0
37
57
141
19
35
– –
–
–
+
+
+ +
All Patients 
Outcome # Rate
No AKI
 AKI > 2d
 AKI > 2d
N=345 
316 
29 
0.92 
0.08
pCysC ≤ 0.8
# RateOutcome 
No AKI
N=169 
160 
9 
0.95
0.05
pCysC > 0.8
# RateOutcome 
No AKI
N=176 
156 
20 
0.89
0.11 AKI > 2d
uNGAL ≤ 200
# RateOutcome 
No AKI
N=150 
148 
2
0.99
0.01 AKI > 2d
uNGAL ≤ 200
# RateOutcome 
No AKI
N=141 
141 
0
1.0
0.0 AKI > 2d
uNGAL ≥ 200
# RateOutcome 
No AKI
N=35 
15 
20
0.43
0.57 AKI > 2d
uNGAL ≥ 200
# RateOutcome 
No AKI
N=19 
12 
7
0.63
0.37 AKI > 2d
Δ SCr
Δ SCr ≤ 45 N=307
Δ SCr > 45%
SCr > 45% n AKI %
–
+
307
38
6
29
uNGAL > 200
pCysC > 0.8
All Patients 
Marker Sensitivity Specificity AUC
Outcome 
Outcome 
# Rate
# Rate
No AKI
No AKI
AKI > 2d
AKI > 2d AKI > 2d
Δ SCr > 45 N=38
Outcome # Rate
No AKI
N=345 
316 
289 27
11
0.71
0.29
0.94
38%
93% 92% 0.95
91% 0.65
0.0618
29 
0.92 
0.08
The terminal node of the supervised decision rules for uNGAL and pCysC shows 57% probability of severe AKI versus 29% for the unsupervised
rule for DSCr (>45%). CART analysis also demonstrated a higher sensitivity, speciﬁcity, and AUC-ROC for the biomarker composite compared
to the creatinine change. Abbreviations as in Figures 1 and 3.
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2759measurements) and is combined with a 2-h mea-
surement of pCysC, the prediction of both severe
AKI and AKI lasting more than 2 days is superior
to that afforded by DSCr (Online Appendix 1).
For instance, optimal ﬂuid management after CPB
generally balances tight regulation of inputs and
outputs on the basis of ﬂuid delivery, post-operative
diuresis, and medication-induced diuresis (diuretic
agents) or mechanical ﬂuid removal (peritoneal dial-
ysis). Using biomarker composites, a patient with
known functional and tubular damage, carrying a
high likelihood of severe and persistent AKI, may be
more expeditiously directed toward a certain modal-
ity of post-operative ﬂuid management, such as ﬂuid
restriction and/or early use of renal replacement
therapy (e.g., peritoneal dialysis or continuous renal
replacement therapy). Although a DSCr of >50% from
baseline to ﬁrst post-operative laboratory value is
modestly predictive of severe AKI or persistent AKI,
changes less than 50% but greater than 0% carry no
statistically signiﬁcant predictive power for either
AKI characteristic.
Identiﬁcation of AKI pathophysiology is possible
using biomarker composites. In the subset of patients
who developed AKI KDIGO stages 2 to 3 (62 of 345 pa-
tients), the absence of tubular damage was highly
predictive of transient, reversible AKI. Conversely, the
presence of tubular damage was highly predictive of
AKI with persistent injury and delayed return to pre-
operative health. Analysis of the different cutoffvalues for SCr demonstrated no statistically signiﬁcant
ability of DSCr to identify transient AKI at any level. A
practitioner caring for a child with a doubling of
creatinine on POD1 would be informed to a greater
degree bymeasurement of a tubular damage-negative/
functional damage-positive composite biomarker at
2 h into CPB than a ﬁrst post-operative DSCr assay with
50% to 100% higher concentrations than baseline. The
diagnosis of pre-renal AKI may be presumptively (and
potentially inaccurately) applied in the context of the
latter, whereas the diagnosis of functional change AKI
would be more precisely (and accurately) applied
in the context of the former.
Decision tree analysis highlighted the probability
for severe and persistent AKI in stratiﬁed pop-
ulations. Comparisons of the most optimal DSCr
cutoff value, determined by unsupervised CART
analysis, to the a priori-determined uNGAL and
pCysC cutoff values demonstrated that the probabil-
ities for each outcome were notably higher in the
terminal nodes for the biomarker composites. Of
the 35 patients with uNGALþ/pCysCþ composites,
89% developed KDIGO stages 2 to 3 within 7 post-
operative days, and 57% experienced persistent
AKI (Figures 3 and 4). Interestingly, although indi-
vidually robust, uNGALþ terminal nodes that were
pCysC carried a lower probability of each outcome
(74% of patients for severe AKI and 37% for persistent
AKI) versus dual positivity. By comparison, less than
one-half of the 72 patients (43%) who had a DSCr of
CENTRAL ILLUSTRATION Combining Biomarker Proﬁles Increases the Predictive Precision of
Acute Kidney Injury Diagnosis
Current Standard of Care
Proposed Standard of Care
Creatinine 
Change
Combination
Biomarker Profile
PredictionPatient
Time
Patient
Time
INJURY
Prediction
AKI
AKI
Presence
Presence
Severity
Duration
Reversibility
x
INJURY
YES
NO
YES
NO
x
Basu, R.K. et al. J Am Coll Cardiol. 2014; 64(25):2753–62.
After a given injury, such as cardiopulmonary bypass, proﬁles created by combining novel tubular damage and functional injury biomarkers
allow clinicians to predict acute kidney injury earlier than the use of changes in creatinine, and with more detail. AKI ¼ acute kidney injury.
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2760>29.2% developed severe AKI, and less than one third
of the 38 patients (29%) who had a DSCr of >45%
experienced persistent AKI. The cutoff values of
29.2% for AKI severity and 45% for AKI persistence
were the optimal values derived from CART for pre-
diction of the outcomes of interest. The discrimina-
tion afforded by the biomarker composites for severe
and persistent AKI, denoted by CART-derived AUC
values, was superior to that afforded by the DSCr AUC
values. Discrepancies between incremental increases
in the AUC after the stepwise addition of each
biomarker to the model and those of the composite
model can be attributed to the nature of the cutoff
determination. The supervised decision rule offered
higher AUC values than the unsupervised individual
decision rules, but in discrimination for both severity
and duration of AKI, the composite biomarker AUC
values were higher than those for individual bio-
markers or DSCr AUC values.
This study operationalized the directives of
the consensus statements calling for the use ofbiomarker combinations to increase the precision of
AKI diagnosis. Strengths of our study include being
the ﬁrst to directly study the directives of the ADQI
classiﬁcations; use of a large sample size; robust dif-
ferences in outcome measurements; and the inter-
pretation of the ﬁndings, carrying the potential to
affect management of a child following CPB. Our
primary outcome metrics were chosen on the basis
of their clinical relevance and to create a reference
more easily followed than the previous nomenclature
(pre-renal versus intrinsic AKI are anecdotally sepa-
rated on the basis of severity and duration of #48 h)
(6). Separation of patients into 1 of 4 biomarker
composite classiﬁcations lends itself directly to
targeted therapy and interventions (e.g., testing
the efﬁcacy of diuretic therapy vs. peritoneal dial-
ysis in ﬂuid balance in patients with uNGALþ/
pCysCþ composite). Previous data suggest a high
progression rate of “mild AKI” (i.e., KDIGO stage 1 or
RIFLE [Risk, Injury, Failure, Loss, End-Stage AKI] R)
to “severe AKI” (i.e., KDIGO stages 2–3 or RIFLE I-F).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Conventional
indicators of AKI, such as a rise in SCr concentration, are delayed
and not speciﬁc to the type of injury involved. Characterization of
these conditions as “pre-renal” or “intrinsic renal disease” is
imprecise and insufﬁcient to guide management. Combinations
of novel biomarkers that react earlier than SCr after AKI may
correlate with speciﬁc sites of injury to the nephron in ways that
could improve classiﬁcation and with implications for clinical
management.
TRANSLATIONAL OUTLOOK: Correlative clinical studies are
needed to integrate biomarker proﬁles for classiﬁcation of AKI
into treatment algorithms applicable to the early management of
patients with renal injury, including pharmacotherapy targeted
toward speciﬁc AKI subtypes on the basis of the predominance
of glomerular or tubular injury.
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2761Our data show that combining novel biomarkers
predicts creatinine-based outcomes with greater
precision than measuring changes of creatinine
itself (10).
STUDY LIMITATIONS. Our study has several limita-
tions. We were limited by the single-center and
retrospective nature of our data collection. Our
population was all post-CPB and relatively homoge-
neous; newer methodology and analyses are
required to extrapolate the ﬁndings for study in
heterogeneous patient populations (24). Validation
in a prospective population outside of our institution
would verify our model and strengthen our ﬁndings.
We deﬁned AKI using the creatinine-based KDIGO
deﬁnition, not by urine output, and we did not
correct SCr for degree of ﬂuid overload. We did
not analyze biomarkers other than those listed
here and readily admit that other novel biomarkers
may carry greater or lesser predictive precision
(10,25). For instance, incorporation of tubular
cell cycle arrest marker tissue inhibitor of matrix
metalloproteinase-2 (TIMP-2) and insulin-like
growth factor binding protein-7 (IGF-BP7) may
further enrich the precision of using biomarker
composites by increasing the granularity of AKI
phenotypes (26). Also, not having earlier creatinine
measurements is a limitation of the study; however,
the routine use of modiﬁed ultraﬁltration before
removal from CPB at our institution limits
the potential of creatinine dilution and undere-
stimation of creatinine changes in the ﬁrst
post-operative measurement. Additionally, we de-
monstrated that biomarker composites created from
measurements at different times (Online Appendix 1)
were consistently superior to initial changes in
creatinine. We normalized uNGAL to urinary
creatinine in our analysis, but separate analysis of
uncorrected uNGAL also demonstrated the perfor-
mance of the biomarker composites was superior to
that of DSCr alone (Online Appendix 2). By high-
lighting the ability to identify transient AKI using
biomarker composites, we assumed that tubular
damage is more indicative of lasting kidney injury
than damage denoted by a functional marker such as
pCysC. When SCr is substituted for pCysC in the
composite, prediction of AKI severity and duration is
more robust than with DSCr alone but less robustthan with the composite of uNGAL and pCysC
(Online Appendix 3).
CONCLUSIONS
Our ﬁndings open the door to the use of novel AKI
biomarkers for improving the precision of AKI diag-
nosis. Future study is needed to investigate whether
biomarker composites can be matched to unique in-
juries. For instance, sepsis-associated AKI may have
a biomarker proﬁle that is distinctly different from
that of nephrotoxin-associated AKI. However, our
work suggests that using novel AKI biomarkers, re-
presentative of different locations of injury within
the nephron and carrying different temporal pro-
ﬁles in relation to injury, may render the ability to
identify AKI phenotypes, on the basis of timing,
severity, and pathophysiology. Ideally, these pheno-
types would lead directly to targeted therapeutic in-
terventions, ultimately attempting to disentangle the
AKI syndrome and ushering in the era of personalized
AKI medicine (14,27).
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